At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 167 enrolled
Drug / intervention
loteprednol etabonate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty
In Brief
A Phase 4 clinical trial evaluating loteprednol etabonate and prednisolone acetate 1% for Fuchs' Dystrophy and Corneal Edema. Completed, enrolled 167 participants across 1 site.
Detailed Summary
Graft rejection has traditionally been one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used for an extended period after transplant surgery. The purpose of this study is to compare the efficacy and side effects of different corticosteroid dosing regimens after endothelial keratoplasty (cornea transplant) surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFuchs' Dystrophy, Corneal Edema
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedMay 2013
Primary CompletionJan 2015
TodayJul 2026
First PostedMay 15, 2013
Enrollment StartMar 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.1 years ago
Interventions
loteprednol etabonatedrug
prednisolone acetate 1%drug